Highlights Orion Oyj

Equities

ORNBV

FI0009014377

Market Closed - Nasdaq Helsinki Other stock markets 11:29:36 2024-05-28 am EDT			After market 03:59:59 pm
37.01 ^EUR	-1.52%		37.05	+0.11%

May. 07	Orion Corporation Announces Change in Orion Group Executive Management Board as of 31 May 2025	CI
Apr. 26	Orion Corporation Announces Appointments to Nomination Committee	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Orion Oyj Revises Earnings Guidance for the Year 2024	Apr. 25	CI
Orion Oyj Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Orion to Continue Reviewing Outsources Options for Finnish Plant as Change Negotiations Complete	Mar. 22	MT
Ex-dividend day for interim dividend	Mar. 20	FA
Orion Corporation Approves Dividend for the Financial Year Ended 31 December 2023, Payable on 3 April 2024 and 23 October 2024	Mar. 20	CI
Orion Unveils Partnership with Save the Children Finland	Feb. 22	MT
Orion Explores Potential Outsourcing of Kuopio Plant’s Production Operations	Feb. 19	MT
Orion Provides FY24 Sales, Operating Profit Guidance	Feb. 13	MT
Orion Oyj Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 13	CI
Orion Oyj Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 13	CI
Orion Oyj Proposes Dividend for the Financial Year Ended on 31 December 2023, Payable on 3 April 2024 and 23 October 2024	Feb. 13	CI
Orion Oyj Provides Earnings Guidance for the Year 2024	Feb. 13	CI
Orion Inks License Deal With Newel Health for Digital Therapeutic	Jan. 29	MT
Orion Corporation and Newel Health Enter into Licensing Agreement for Digital Therapeutic(DTx) ODD-403 (?Rohkea?) in pain	Jan. 29	CI
Orion Flags EUR31 Million Gain in FY23 from Pension Fund’s Insurance Portfolio Transfer	Jan. 11	MT
Orion, Glykos Finland Tie Up for Development of Antibody-drug Conjugates	Jan. 08	MT
Orion Corporation and Glykos Finland Oy Announce Research Collaboration and Licensing Agreement to Develop Next-Generation Adcs	Jan. 08	CI
Navamedic Enters Agreement with Orion for Distribution of Parkinson's Drug Across Europe	Dec. 14	MT
Navamedic ASA and Orion Corporation Sign Non-Binding Term Sheet for Flexilev® in Europe	Dec. 13	CI
Orion Corporation Announces Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov Database	Nov. 21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Orion Oyj

Equities

ORNBV

FI0009014377

Highlights

Filters